ProCE Banner Activity

CE / CME

Interventions to Protect the High-Risk Patient From Invasive Fungal Infections

Multimedia
This interactive video module examines risk stratification, nonpharmacologic strategies to reduce fungal exposure, guideline recommendations for prophylactic therapy, and management of breakthrough infections.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: April 24, 2019

Expiration: April 23, 2020

No longer available for credit.

Share

Faculty

Thomas F. Patterson

Thomas F. Patterson, MD, FACP, FIDSA

Professor and Chief
Division of Infectious Diseases
Department of Medicine
The University of Texas Health Science Center at San Antonio
San Antonio, Texas

James Lewis

James Lewis, MD

Professor of Medicine
Director of Hepatology
Georgetown University Medical Center
Washington, DC

George R. Thompson III

George R. Thompson III, MD, FIDSA

Associate Professor of Medicine
Division of Infectious Diseases
Department of Internal Medicine
Department of Medical Microbiology and Immunology
University of California – Davis Health
Sacramento, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Astellas Text

Target Audience

This program is intended for infectious diseases specialists, pulmonologists, intensive care clinicians, hematology/oncology specialists, pharmacists, nurses, and other healthcare providers who care for patients with or at risk for invasive fungal infections.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize the evidence that supports the initiation of antifungal chemoprophylaxis in certain high-risk patients

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Thomas F. Patterson, MD, FACP, FIDSA

Professor and Chief
Division of Infectious Diseases
Department of Medicine
The University of Texas Health Science Center at San Antonio
San Antonio, Texas

Thomas F. Patterson, MD, FACP, FIDSA, has disclosed that he has received consulting fees from Basilea, Gilead Sciences, Merck, and Scynexis and funds for research support from Cidara.

Faculty Disclosure

Primary Author

James Lewis, MD

Professor of Medicine
Director of Hepatology
Georgetown University Medical Center
Washington, DC

James Lewis, PharmD, FIDSA, has disclosed that he has received consulting fees from Merck.

George R. Thompson III, MD, FIDSA

Associate Professor of Medicine
Division of Infectious Diseases
Department of Internal Medicine
Department of Medical Microbiology and Immunology
University of California – Davis Health
Sacramento, California

George R. Thompson III, MD, FIDSA, has disclosed that he has received consulting fees and funds for research support from Amplyx, Astellas, Cidara, F2G, and Scynexis.

Staff Disclosure

Staff

Ashley Bohn, PhD, MS, RVT

Clinical Editor

Ashley Bohn, PhD, MS, RVT, has disclosed that she has received fees for non-CME/CE activities from Genomic Health, Lilly, and Merck.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran Mir-Hudgeons, PhD, has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this activity is 1.0 contact hours.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-002-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 24, 2019, through April 23, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in applying current and emerging treatment strategies in the management of severely immunocompromised patients at risk for invasive fungal infections.